Literature DB >> 16779467

Suppurative mediastinitis secondary to Burkholderia cepacia in a patient with cystic fibrosis.

Ronald B George1, Yannick Cartier, Alan G Casson, Paul Hernandez.   

Abstract

Burkholderia cepacia is an important opportunistic pathogen among patients with cystic fibrosis (CF); it is associated with deterioration of lung function, poor outcome following lung transplantation and increased mortality. Fever, an elevated white blood cell count, weight loss and an often fatal deterioration in pulmonary function characterize a particular clinical course, termed "Cepacia syndrome". The present case report describes a 40-year-old man with CF who developed Cepacia syndrome complicated by suppurative mediastinitis, from which B cepacia was isolated. Despite optimal medical and surgical therapy, this patient succumbed to his illness. Those caring for patients with CF should be aware of this potentially catastrophic complication of B cepacia infection, especially in the setting of Cepacia syndrome.

Entities:  

Mesh:

Year:  2006        PMID: 16779467      PMCID: PMC2683282          DOI: 10.1155/2006/495720

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  16 in total

1.  Burkholderia cepacia infections in cystic fibrosis.

Authors:  J L Burns; L Saiman
Journal:  Pediatr Infect Dis J       Date:  1999-02       Impact factor: 2.129

2.  Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation.

Authors:  C Chaparro; J Maurer; C Gutierrez; M Krajden; C Chan; T Winton; S Keshavjee; M Scavuzzo; E Tullis; M Hutcheon; S Kesten
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

3.  Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis.

Authors:  S K Fung; H Dick; H Devlin; E Tullis
Journal:  Can J Infect Dis       Date:  1998-05

4.  Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients.

Authors:  Umadevi Sajjan; Mary Corey; Atul Humar; Elizabeth Tullis; Ernest Cutz; Cameron Ackerley; Janet Forstner
Journal:  J Med Microbiol       Date:  2001-06       Impact factor: 2.472

Review 5.  Advances in Burkholderia cepacia complex.

Authors:  David Paul Speert
Journal:  Paediatr Respir Rev       Date:  2002-09       Impact factor: 2.726

6.  Reinfection, rather than persistent infection, in patients with chronic granulomatous disease.

Authors:  Shireen V Guide; Frida Stock; Vee J Gill; Victoria L Anderson; Harry L Malech; John I Gallin; Steven M Holland
Journal:  J Infect Dis       Date:  2003-02-24       Impact factor: 5.226

7.  Cepacia-like syndrome caused by Burkholderia multivorans.

Authors:  George Zahariadis; Michelle H Levy; Jane L Burns
Journal:  Can J Infect Dis       Date:  2003-03

8.  Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes.

Authors:  O C Tablan; W J Martone; C F Doershuk; R C Stern; M J Thomassen; J D Klinger; J W White; L A Carson; W R Jarvis
Journal:  Chest       Date:  1987-04       Impact factor: 9.410

9.  Pseudomonas cepacia in lung transplant recipients with cystic fibrosis.

Authors:  G I Snell; A de Hoyos; M Krajden; T Winton; J R Maurer
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

10.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more
  4 in total

1.  Cystic fibrosis, a Burkholderia cenocepacia chest wall abscess and rapid clinical deterioration.

Authors:  N J Simmonds; K M Gyi
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

2.  Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; C B Landersdorfer; S J Hüttner; G L Drusano; M Kinzig; U Holzgrabe; U Stephan; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

3.  Ralstonia mannitolilytica in cystic fibrosis: A new predictor of worse outcomes.

Authors:  I Coman; L Bilodeau; A Lavoie; M Carricart; F Tremblay; J E Zlosnik; Y Berthiaume
Journal:  Respir Med Case Rep       Date:  2016-12-03

Review 4.  Burkholderia vaccines: are we moving forward?

Authors:  Leang-Chung Choh; Guang-Han Ong; Kumutha M Vellasamy; Kaveena Kalaiselvam; Wen-Tyng Kang; Anis R Al-Maleki; Vanitha Mariappan; Jamuna Vadivelu
Journal:  Front Cell Infect Microbiol       Date:  2013-02-05       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.